Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...

Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Gilead in 2021 won the FDA accelerated nod for Trodelvy in metastatic urothelial cancer, but continued approval was contingent on the outcome of a confirmatory study. The company in late May said that ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

The company's HIV drug, lenacapavir, showed a 96% reduction in HIV infections in a Phase 3 trial, outperforming daily oral medication Truvada. Gilead plans to file for approval of lenacapavir by ...

is pleased to announce that it is providing an update on its bladder cancer clinical study. Theralase®'s lead drug, Ruvidar TM, activated by the TLC-3200 Medical Laser System ("TLC-3200") is ...

STOCKHOLM — Cancer research or drugs treating cardiovascular illnesses could win a Nobel Prize on Monday when a week of laureate announcements kicks off, bringing a ray of optimism to a world beset by ...